Указатели 4 тома (2002)
Saved in:
| Published in: | Онкологія |
|---|---|
| Date: | 2002 |
| Format: | Article |
| Language: | Russian |
| Published: |
Iнститут експериментальної патології, онкології і радіобіології ім. Р. Є. Кавецького
2002
|
| Subjects: | |
| Online Access: | https://nasplib.isofts.kiev.ua/handle/123456789/24717 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Cite this: | Указатели 4 тома (2002) / // Онкологія. — 2002. — Т. 4, № 4. — С. 315-320. — Бібліогр.: 0 назв. — рос. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1860270668729286656 |
|---|---|
| citation_txt | Указатели 4 тома (2002) / // Онкологія. — 2002. — Т. 4, № 4. — С. 315-320. — Бібліогр.: 0 назв. — рос. |
| collection | DSpace DC |
| container_title | Онкологія |
| first_indexed | 2025-12-07T19:06:03Z |
| format | Article |
| fulltext |
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002 315
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
ÀÂÒÎÐÑÊÈÉ ÓÊÀÇÀÒÅËÜ
À
Àáðàìåíêî È.Â., 165
Àëåêñàíäðîâ À.Ë., 271
Àëåêñååíêî Î.È., 252
Àëåêñèê Å.Ì., 135
Àë³ñòðàòîâ Î.Â., 188
Àíîøèíà Ì.Þ., 29
Àðòþøåíêî Ë.Ò., 232
Á
Áàáàíëè Ø.Ð., 281
Áàëèöêàÿ Î.Â., 225
Áàð³ëêà Â.À., 25
Áàñîâà Î.Â., 29
Áàøååâ Â.Õ., 59
Áåáåøêî Â.Ã., 217
Áåëûé À.Í., 113
Áåðåæíàÿ Í.Ì., 99, 263
Áåøëÿãà Â.Ì., 228, 306
Áèáà À.Ï., 130
Á³ëèíñüêèé Á.Ò., 159
Áîëãîâà Ë.Ñ., 225, 252
Áîíäàðü Ã.Â., 59, 121
Áîðîòà À.Â., 59, 121
Áóãàéöîâ Ñ.Ã., 103
Áó÷èíñüêà Ë.Ã., 18, 238
Â
Âàêóëü÷óê À.Ì., 29
Âàëåöêèé Â.Ë., 117
Âàñèëüåâ Ñ.Ä., 59
Âàñèëþê Î.Ì., 209
Âàòèí Î.Å., 109
Âåëè÷êî Ë.Í., 259
Âèãîâñüêà ß.²., 25, 89,
256
Âèëü÷åâñêàÿ Å.Â., 212
Âèííè÷óê Þ.Ä., 99
Âèò Â.Â., 259
Âèòîâñêèé Ð.Ì., 228,
306
³â÷àðåíêî Þ.Ê., 49
³ííèöüêà À.Á., 40, 188
Âîâê Ã.Ï., 234
Âîëêîâ ².Á., 209
Âîëîøèí Í.À., 21
Âîðîáüåâà Ë.È., 70
Âîðîíöîâà À.Ë., 200
Ã
Ãàâðèëþê Þ.É., 94
Ãåðòìàí Â.Ç., 236
Ãëèíñüêà Î.Â., 234, 256
Ãîïêî ß.Þ., 228
Ãîðáóíîâà Â.À., 285
Ãîðëóøêî Ì.Ì., 128
Ãîðîáåéêî Ì.Á., 197
Ãðåñüêî ².Â., 49
Ãðèãîðîâñüêèé Â.Â.,
174
Ãðèíåâè÷ Þ.À., 117
Ãóáàðåâà À.À., 135
Ãóëàê Ë.Î., 46, 128, 275
Ãóí³íà Ë.Ì., 293
Ä
Äàâèäþê Â.Á., 200
Äàíêî Ì.È., 117
Äàöóí À.²., 49
Äåäêîâ À.Ã., 209, 277
Äåõòÿð Ò.Â., 268
Äæóæà Ä.À., 197
Äçÿòêîâñêàÿ Í.Í., 117
Äîìáðîâè÷ Ì.²., 281
Äîðîø Î.²., 234, 256
Äðàãîìèðåöêàÿ Å.È.,
259
Äðèæàê Â.²., 160, 281
Äðîçäîâ Â.Ì., 33, 99
Äóáåé Ë.ß., 234
Äóäíè÷åíêî À.Ñ., 191
Å, ª
Åìåö È.Í., 228
ªâñòàõåâè÷ ².É., 89
ªâòóøåíêî Î.²., 46,
128, 204, 275
Æ
Æèëü÷óê Â.ª., 200
Ç
Çàáàðêî Ë.Á., 184
Çàâèçèîí Â.Ô., 232
Çàãóðñüêà Í.Î., 281
Çàõàðîâà Â.Ï., 306
Çàõàðöåâà Ë.Ì., 33, 99,
184, 263
Çîëîòóõèí Ñ.Ý., 59, 121
È, ²
Èùåíêî Ð.Â., 15
Ê
Êàíèùåâà È.Í., 113
Êàðîëü Þ.Ñ., 25, 89
Êàñüÿíåíêî ².Â., 268
Êàòåðèíè÷ À.À., 33
Êèêîòü Â.Â., 275
Êèêîòü Â.Î., 46, 128, 275
Êèòîâ Í.Â., 130
ʳöåðà Í.²., 94
Êëåâåòåíêî Ì.Ï., 184
Êëèìåíêî ².Î., 268
Êëèìåíêî Ñ.Â., 217
Êíÿçåâà Î.Á., 277
Êîâàëü÷óê Å.Â., 99
Êîâàëü÷óê Ý.Í., 225
Êîçëåíêî À.Â., 99
Êîëåñíèê Å.À., 59, 121
Êîëåñíèê Î.Î., 46
Êîëîòèëîâ Í.Í., 107
Êîíåâ Â.Ã., 62, 130
Êîíîâàëåíêî Â.Ô., 209
Êîðîáêî Â.Á., 138, 299
Êîðîâ³í Ñ.²., 209, 277
Êîñò³íñüêèé ².Þ., 49
Êðàâ÷åíêî À.Â., 56
Êðàâ÷åíêî Â.È., 228
Êðèêóíîâ À.À., 306
Êðèêóíîâà Ë.È., 109
Êðþ÷èíà Å.À., 56
Êóçüìèíà Å.Ã., 109
Êóëèê Ã.²., 4, 311
Êóòëóìóðàòîâ À.Á., 171
Ë
Ëàðèí À.Ñ., 197
Ëåáåäü Ã.Á., 89, 256
Ëåâèê Í.Í., 21
Ëåâêîâñüêèé Ñ.À., 200
Ëèãà Î.Â., 94
˳ñíÿê ².Î., 188, 244
Ëîã³íñüêèé Â.O., 25, 89,
256
Ëóðèí È.À., 130
Ì
Ì’ÿñîºäîâ Ä.Â., 204
Ìàêñèì’ÿê Ã.²., 200
Ìàëååâ Î.Â., 107
Ìàë³ìîí Þ.²., 132
Ìàðêåâè÷ Í.Â., 94
Ìàòëàí Â.Ë., 25, 89
Ìàöèê Ã.Â., 234
Ìîøèíñêàÿ Î.Â., 29
Ìåäèíåö Þ.Ð., 277
Ìíèøåíêî Â.Í., 29
Í
Íàëºñê³íà Ë.À., 184,
238
Íåéêî ª.Ì., 49
Íåéìàí À.Ì., 33
Íåïðèíà Ã.Ñ., 109
Íåñèíà È.Ï., 9, 18
Íåñïðÿäüêî Ñ.Â., 188
Íå÷àé Â.Ñ., 130
Íîâàê Â.Ë., 89
Íîâàê Î.ª., 9, 184, 244
Íîâàê Ñ.Â., 25
O
Îëèéíè÷åíêî Ã.Ï., 33,
268
Îðåë Â.Ý., 117
Îñèíñêèé Ä.Ñ., 138, 299
Îñèíñêèé Ñ.Ï., 288
Ï
Ïàâëåíêî Þ.Â., 135
Ïàë³âåöü À.Þ., 209, 277
Ïàíàñþê À.À., 277
Ïàùåíêî Ñ.Í., 21
Ïåðåïº÷ê³íà Â.Ò., 209
Ïåòðóõ À.Â., 234, 256
Ïåòðóõèí Â.È., 33
ϳâíþê Â.Ì., 268
Ïîëèùóê Å.Â., 277
Ïîë³ùóê Ë.Ç., 9, 18,
184, 238
Ïîë³ùóê Ð.Ñ., 94, 234,
256
Ïðèéìàê Â.Â., 46, 128
Ïðîòîïîïîâ À.Î., 132
Ïðîöåíêî Â.Â., 209, 277
Ïñàðàñ Ã.Ã., 59, 121
Ïóøêàðü Ñ.Í., 236
Ð
Ðà÷èíñüêà Í.Î., 234
Ðîãîâà Í.Ì., 109
Ðîçåíôåëüä Ë.Ã., 107
Ðîìàíåíêî À.Ì., 184
Ðîìàíþê À.Í., 228
Ðóäàÿ Î.È., 225
Ðóäåíêî Å.Â., 228, 306
Ñ
Ñåíèøèí Í.²., 234
Ñåíüêî Ë.Í., 138
Ñåíþòîâè÷ Ð.Â., 79
Ñèâêîâè÷ Ñ.À., 135
Ñèìîíîâà Ë.È., 236
Ñèíÿâèíà Ë.Â., 191
Ñèðîòêèíà Í.Ï., 109
Ñêîðîïàä Ë.Ë., 94
Ñëûíüêî Å.È., 42
Ñìàêîâà Ì.Ñ., 225
Ñìîëàíêà È.È., 225
Ñîçîíþê Ë.²., 200
Ñîëîâüåâ È.Å., 52, 123
Ñîðêèí Â.Ì., 271
Ñîðîêèíà Ê.Å., 135
Ñîðîê³í Á.Â., 46, 128
Ñïèâàê Ñ.È., 99
Ñòàðèêîâ Â.È., 113
Ñòåïàíþê, Î.²., 94
Ñóïðóíåöü Â.Ë., 132
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002316
A
àä’þâàíòíà òåðàï³ÿ, 40,
66
àäúþâàíòíûé ðåæèì,
215
àëêèëèðóþùèå àãåíòû,
217
àíã³îãåíåç, 244
àíåì³ÿ, 293
àíòèàíã³îãåííà òåðàï³ÿ,
244
àíòèãåí ÿäåð ïðîë³ôå-
ðóþ÷èõ êë³òèí
(PCNA), 184
àíòèãåíè ãðóï êðîâ³,
234
àïîïòîç, 165
Á
áëàñòí³ êë³òèíè, 256
Â
âåíîçíûå òðîìáîýìáî-
ëè÷åñêèå îñëîæíå-
íèÿ, 70
âèëî÷êîâàÿ æåëåçà,
252
â³íêðèñòèí, 89
âíóòðèàðòåðèàëüíàÿ
ïîëèõèìèîòåðàïèÿ,
277
âíóòð³øíüîàðòåð³àëüíà
ïîë³õ³ì³îòåðàï³ÿ,
128
âîñïàëèòåëüíûå îñëîæ-
íåíèÿ, 121
âòîðè÷íàÿ ëåéêåìèÿ,
217
âûæèâàåìîñòü áîëü-
íûõ, 165
Ã
ãåìàòîîíêîëîã³÷í³ çà-
õâîðþâàííÿ, 94
ãåìîðåîëîã³ÿ, 293
ãåíåòè÷í³ ìóòàö³¿, 234
ãåíû — ñóïðåññîðû
îïóõîëåâîãî ðîñòà, 9
HER-2/neu, 33, 263
ã³ãàíòîêë³òèíí³ ïðî-
ë³ôåðàòèâí³ óðàæåí-
íÿ ê³ñòîê, 174
ã³äðîêñèëàïàòèò, 209
ãèïåðòåðìèÿ (ëîêàëü-
íàÿ, îáùàÿ), 288
ã³ñòîïàòîëîã³ÿ, 174
ãëèîìû ãîëîâíîãî ìîçãà,
194
ãîäè÷íàÿ âûæèâàå-
ìîñòü, 117
ãîðìîíàëüíàÿ òåðàïèÿ,
99, 271
ãîñòðà ë³ìôîáëàñòíà
ëåéêåì³ÿ ó ä³òåé, 256
Ä
äàëàðãèí, 107
äåïðåññèÿ, 103
äèàãíîñòèêà, 151, 228,
306
äèàãíîñòè÷åñêàÿ ýô-
ôåêòèâíîñòü, 113
äèñêðèìèíàíòíûé àíà-
ëèç, 52, 123, 259
äèñëèïîïðîòåèíåìèè,
236
äèôåðåíö³éíà ã³ñòîëî-
ã³÷íà ä³àãíîñòèêà,
174
äèôôåðåíöèðîâàííûé
ðàê ùèòîâèäíîé æå-
ëåçû, 197
äèôôóçèîííûå êàìå-
ðû, 99, 263
ä³òè, 94
äîöåòàêñåë (ÒÀÊÑÎ-
ÒÅÐ), 66, 84, 215
Å, ª
åíòåðîñîðáåíòè, 49
åôåêòèâí³ñòü, 40, 46,
132, 268
Ç
çàáîëåâàåìîñòü, 171
çëîêà÷åñòâåííûå íîâî-
îáðàçîâàíèÿ, 56, 70
çëîÿê³ñí³ ë³ìôîìè, 25
çëîÿê³ñí³ ïóõëèíè
ê³ñòîê, 209
çëîÿê³ñí³ ïóõëèíè, 244,
293
È, ²
èììóíîãðàììà, 117
èììóíîêîððåêöèÿ, 109
èììóíîëîãè÷åñêèå
ïîêàçàòåëè, 259
èíãèáèòîðû ÄÍÊ
òîïîèçîìåðàçû II,
217
èíäèâèäóàëüíàÿ ÷óâ-
ñòâèòåëüíîñòü, 15
èíäóêòîðû èíòåðôåðî-
íà, 194
èíòåðôåðîíîãåíåç, 194
èîíèçèðóþùàÿ ðàäèà-
öèÿ, 217
èðèíîòåêàí (ÊÀÌÏ-
ÒÎ), 62, 84, 285
³ìóííà öèòîïåí³ÿ, 89
³ìóíîã³ñòîõ³ì³ÿ, 174
³ìóíîôåíîòèï, 256
³ìóíîôåðìåíòíèé ìå-
òîä, 188
³íòåðëåéê³í-2, 25
³íòåðôåðîí, 200
³íòðàîïåðàö³éíà êð³î-
äåñòðóêö³ÿ òà ñïîí-
òàííå â³äòàþâàííÿ,
204
Ê
êåðàì³÷íèé ìàòåð³àë,
209
ê³ñòêîâî-ïëàñòè÷í³
îïåðàö³¿, 209
êëåòî÷íûé òèï, 259
êëèíèêî-ìîðôîëîãè-
÷åñêèå ïîêàçàòåëè,
259
êëèíè÷åñêèå èñïûòà-
íèÿ, 66, 84, 215
êëîäðîíîâà êèñëîòà,
268
êîëîðåêòàëüíûé ðàê,
62, 84, 130
êîìá³íîâàíå ë³êóâàííÿ,
40, 128, 204
êîìá³íîâàí³ ìåòîäè, 46
êîìïüþòåðíàÿ òîìî-
ãðàôèÿ, 113
êóëüòèâèðîâàíèå, 99,
263
Ë
ëåéêåì³ÿ, 234
ëåéêîïåíèÿ, 135
ëåêòèíû, 21
ëå÷åíèå, 151
ëèìôîãðàíóëåìàòîç,
135
ëèìôîèäíàÿ òèìîìà,
252
Ñóñàê ß.Ì., 56
Ñóõîâåðøà À.À., 232
Ò
Òàðàñîâà Ò.À., 277
Òàùóê ².Â., 37
Òêà÷åíêî Í.²., 18
Òîäîð ².Ì., 4
Òîëñòîï’ÿòîâ Á.Î., 209,
277
Òîìèëèíà Í.À., 135
Òîôàí À.Â., 52, 123
Òðåòÿê Í.Í., 29
Òðèíäÿê Â.Ï., 4
Òðîÿíîâñüêà Î.Î., 94,
234
Òðóõèí Ä.Â., 121
Òóãàíîâà Ò.Í., 225, 252
Ó
Óñàòîâ Ñ.À., 194
Ô
Ôèëü÷åíêîâ À.À., 165
Ö
Öèìáàëþê ².Ï., 94
Öèï Í.Ï., 74
Öÿïêà Î.Ì., 89
×
×åðåíüêî Ñ.Ì., 197
×åðèïêî Î.Í., 206
×åðíûé Â.À., 46, 52, 78,
117, 123, 128, 138, 299
×åõóí Â.Ô., 4, 188, 244,
268, 311
×åøóê Â.Å., 99, 263
×èøêåâè÷ Þ.Â., 200
Ø
Øàáåëÿíñüêèé Â.Á., 132
Øàë³ìîâ Ñ.Î., 204
Øïàðèê ß.Â., 145
Øóäðàê À.À., 130
Ùåïîòèí È.Á., 151
Þ
Þãð³íîâ Î.Ã., 128, 299
Þñóïîâ Á.Þ., 171
ß
ßãîâäèê Ì.Â., 29
ßêèì÷óê Ï.Ì., 200
ßðåì÷óê À.ß., 99
ßðîøåíêî Ì.Â., 59
ÓÊÀÇÀÒÅËÜ ÊËÞ×ÅÂÛÕ ÑËÎÂ
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002 317
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
ëèìôîèäíûå êëåòêè,
252
ëèïîïðîòåèäû, 191
ë³ìôîê³íàêòèâîâàíà
öèòîòîêñè÷í³ñòü,
25
ë³ìôîöèòè, 18, 25
ëîêàëüíàÿ ãèïåðòåðìèÿ
(ìàãíèòîòåðìèÿ),
277
ëó÷åâàÿ òåðàïèÿ, 107,
135, 277
Ì
ìàãíèòíî-ðåçîíàíñíàÿ
òîìîãðàôèÿ, 113
ìàñòýêòîìèÿ, 103
ÌÅÁÈÔÎÍ, 268
ìåçîòåëèîìà, 165
ìåëàòîí³í, 37
ìåëêîêëåòî÷íûé ðàê
ëåãêîãî, 285
ìåìáðàíè åðèòðîöèò³â,
293
ìåòàñòàçèðîâàíèå, 21,
293
ìåòàñòàçû, 62, 268
ìåòàôèëàêòèêà, 107
ìåòîäèêà in vitro, 15
ìåòîòðåêñàò, 212
ìåõàíèçìû äåéñòâèÿ,
288
ìíîæåñòâåííàÿ ìèåëî-
ìà, 29
ìîëî÷íàÿ æåëåçà, 191
ìîðôîëîãèÿ, 9, 306
ìîðôîìåòðèÿ, 252
Í
íåîàä’þâàíòíà òåðàï³ÿ,
40, 66
íåîàä’þâàíòíà ïîë³-
õ³ì³îòåðàï³ÿ, 37
íåîïåðàáåëüíàÿ îïó-
õîëü, 138
íåïðÿìå åëåêòðîõ³ì³÷-
íå îêèñëåííÿ êðîâ³,
281
íèçêàÿ áðþøíî-àíàëü-
íàÿ ðåçåêöèÿ, 59
íèçüêîåíåðãåòè÷íà ëà-
çåðîòåðàï³ÿ, 281
íîðìàëüí³ òà ïóõëèíí³
êë³òèíè, 4
O
îáùèé õîëåñòåðèí, 191
îíêîãåíû, 9
îïóõîëè æåíñêîé ðåï-
ðîäóêòèâíîé ñèñòå-
ìû, 165
îïóõîëè ìîçãà, 165
îïóõîëè ìÿãêèõ òêà-
íåé, 165
îïóõîëè îðãàíîâ äûõà-
íèÿ, 165
îïóõîëè îðãàíîâ ìî÷å-
ïîëîâîé ñèñòåìû,
165
îïóõîëè îðãàíîâ ïèùå-
âàðèòåëüíîãî òðàê-
òà, 165
îïóõîëè ñåðäöà, 228,
306
îïóõîëè ñðåäîñòåíèÿ,
113
îðãàíîçáåð³ãàþ÷å ë³êó-
âàííÿ, 132, 200
îñòàòî÷íàÿ òêàíü ùè-
òîâèäíîé æåëåçû,
197
îñòðàÿ êèøå÷íàÿ íå-
ïðîõîäèìîñòü, 52,
123
îñòðûé ëèìôîáëàñò-
íûé ëåéêîç ó äåòåé,
212
îñòðûé ïàíêðåàòèò, 56
îöåíêà ýôôåêòèâíîñ-
òè, 121
Ï
ïàïèëëÿðíàÿ ôèáðî-
ýëàñòîìà, 306
ïåðâè÷íî-ìíîæåñòâåí-
íûå çëîêà÷åñòâåí-
íûå îïóõîëè, 271
ïåðåêèñíå îêèñíåííÿ
ë³ï³ä³â, 29, 293
ïåðåõîäíûå è çëîêà÷å-
ñòâåííûå ñïèíàëü-
íûå ñîñóäèñòûå
îïóõîëè, 42
ïå÷åíü, 62
ïëàçìà êðîâè, 25, 29
ïëàçìàòè÷íà ìåìáðàíà,
4
ïîáî÷íûå ðåàêöèè, 212
ÏÎËÈÄÀÍ, 109, 135
ïîëèõèìèîòåðàïèÿ,
109, 135
ïîñëåîïåðàöèîííàÿ
èììóíîòåðàïèÿ, 117
ïîòåðÿ ãåòåðîçèãîòíîñ-
òè, 9
ïðîãíîç, 9, 206
ïðîãíîñòè÷åñêèå êðè-
òåðèè, 29
ïðîëèôåðàöèÿ, 165
ïðîë³ôåðàòèâíà àê-
òèâí³ñòü ïóõëèííèõ
êë³òèí, 184
ïðîìåíåâà òåðàï³ÿ, 49,
209
ïðîòèâîîïóõîëåâàÿ òå-
ðàïèÿ, 288
ïðîòèâîîïóõîëåâàÿ õè-
ìèîòåðàïèÿ, 15
ïðîôèëàêòèêà, 70, 130,
151, 232
ïñèõîðåàáèëèòàöèÿ,
103
ïñèõîñîìàòèêà, 103
ïóçûðíûé çàíîñ, 74
ïóõëèíè òà ïóõëèíî-
ïîä³áí³ óðàæåííÿ
ê³ñòîê, 174
Ð
ðàáäîìèîìû, 228
ðàäèêàëüíå ë³êóâàííÿ,
46
ðàäèîéîäòåðàïèÿ, 197
ðàä³îìîäèô³êàòîðè, 49
ðàê ãëîòêè, 107
ðàê ãîðòàíè, 107
ðàê æåëóäêà, 84, 117,
151
ðàê ëåãêîãî, 232
ðàê ìîëî÷íî¿ çàëîçè,
21, 33, 37, 66, 84, 99,
103, 132, 145, 165,
200, 215, 232, 236,
263, 268, 271
ðàê îáîäîâî¿ êèøêè,
46, 52, 123, 128, 204,
275
ðàê ïåðåäì³õóðîâî¿ çà-
ëîçè, 268
ðàê ïîäæåëóäî÷íîé æå-
ëåçû, 138, 299
ðàê ïðÿìî¿ êèøêè, 49,
59, 121, 206
ðàê ò³ëà ìàòêè, 18, 188
ðàê øåéêè èëè òåëà
ìàòêè, 109
ðàê øèéêè ìàòêè, 40,
188
ðàê ùèòîâèäíîé æåëå-
çû, 171
ðàê ÿè÷íèêà, 9, 84, 109
ðàê, 191
ðàêîâà ³íòîêñèêàö³ÿ,
281
ðåãèîíàðíàÿ õèìèîòå-
ðàïèÿ, 299
ðåçóëüòàòû ëå÷åíèÿ,
138, 299
ðåíòãåíîëîãè÷åñêîå
èññëåäîâàíèå, 113
ðåöåïòîð CD95, 89
ðåöåïòîðû ýñòðîãåíîâ
è ïðîãåñòåðîíà, 33,
99, 263
ðåöåïòîðû, 21
ðåöèäèâ, 206, 209
C
ñàðêîìà ìÿãêèõ òêà-
íåé, 277
ñåðîçí³ íîâîóòâîðåííÿ
ÿº÷íèêà, 184
ñèíäðîì Nijmegen
Breakage, 94
ñèíãëåòíî-êèñíåâà òå-
ðàï³ÿ, 49
ñèñòåìà ñèãíàëüíî¿
òðàíñäóêö³¿, 4
ñèñòåìè ÀÂ0 òà Rh,
234
ñïëåíåêòîì³ÿ, 89
ñõåìà CMF, 145
T
òåðàïèåîáóñëîâëåííàÿ
ëåéêåìèÿ, 217
òåðìîãðàôèÿ, 107
òèðåîèäýêòîìèÿ, 197
òîïîòåêàí, 285
òðèãëèöåðèäû, 191
òðîìáîýìáîëè÷åñêèå
îñëîæíåíèÿ, 130,
232
Ó
óâåàëüíàÿ ìåëàíîìà,
259
Óçáåêèñòàí, 171
óëüòðàô³îëåòîâå îïðî-
ì³íåííÿ êðîâ³, 281
óñêëàäíåííÿ, 132, 209
Ô
ôàêòîð ðîñòó åíäîòåë³-
àëüíèõ êë³òèí
(VEGF), 188, 244
ôàêòîðè ïðîãíîçó,
275
ôàêòîðû ðèñêà, 74
ôèáðîàäåíîìà, 191
ôèáðîçíî-êèñòîçíàÿ
ìàñòîïàòèÿ, 191
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002318
À
Abramenko I.V., 170
Aleksandrov A.L., 274
Alekseenko O.I., 255
Aleksik E.M., 137
Alistratov O.V., 190
Anoshina M.Yu., 32
Artyushenko L.T., 233
B
Babanli S.R., 284
Balitskaya O.V., 227
Barilka V.A., 28
Basheev V.H., 61
Basova O.V., 32
Bebeshko V.G., 224
Bely A.N., 116
Berezhnaya N.M., 102,
267
Beshliaga V.M., 231, 310
Biba A.P., 131
Bilynsky B.T., 159
Bolgova L.S., 227, 255
Bondar G.V., 61, 122
Borota A.V., 61, 122
Buchinska L.G., 20, 239
Bugaitsov S.G., 106
C
Chekhun V.F., 8, 190,
251, 270, 311
Cherenko S.M., 199
Cheripko O.N., 208
Chorny V.O., 48, 55, 78,
120, 127, 129, 144,
305
Cheshuk V.E., 102, 267
Chyshkevich Yu.V., 203
D
Danko M.I., 120
Datsun A.I., 51
Davydiuk V.B., 203
Dedkov A.G., 280
Dekhtiar T.V., 270
Dombrovich M.I., 284
Dorosh O.²., 235, 258
Dragomiretskaya E.I.,
262
Drozdov V.M., 36, 102
Dryzhak V.I., 160, 284
Dubey L.Ya., 235
Dudnichenko A.S., 193
Dyedkov A.G., 211
Dzhuzha D.A., 199
Dziatkovskaya N.N., 120
Å
Eustakhevych I.J., 93
Evtushenko O.I., 48, 129,
276
G
Gavryliuk Yu.J., 98
Gertman V.Z., 237
Glynska O.V., 235, 258
Gopko Ya.Yu., 231
Gorbunova V.A., 287
Gorlushko M.M., 129
Gorobejko M.B., 199
Goulak L.O., 48, 129, 276
Gresko I.V., 51
Grinevich Yu.A., 120
Gubareva A.A., 137
Gunina L.M., 298
I
Ischenko R.V., 17
Ê
Kanischeva I.N., 116
Karol Yu.S., 28, 93
Kasianenko I.V., 270
Katerinich A.A., 36
Kikot V.O., 48, 129, 276
Kikot V.V., 276
Kitov N.V., 131
Kitsera N.²., 98
Klevetenko M.P., 187
Klimenko I.O., 270
Klimenko S.V., 224
Kniazeva O.B., 280
Kolesnik E.A., 61, 122
Kolesnyk O.O., 48
Kolotilov N.N., 108
Konev V.G., 65, 131
Konovalenko V.F., 211
Korobko V.B., 144, 305
Korovin S.I., 211, 280
Kostinskiy I.Yu., 51
Kovalchouk, E.N., 227
Kovalchouk E.V., 102
Kozlenko A.V., 102
Êràvñhånkî A.V., 58
Kravchenko V.I., 231
Krikunov A.A., 310
Krikunova L.I., 112
Kriuñhinà E.A., 58
Kulik G.I., 8, 311
Kutlumuratov A.B., 173
Kuzmina E.G., 112
L
Larin A.S., 199
Lebed G.B., 93, 258
Levik N.N., 24
Levkovsky S.A., 203
Lisniak I.O., 190, 251
Loginsky V.O., 28, 93,
258
Lurin I.A., 131
Lyga O.V., 98
Ì
Maksymjak G.I., 203
Maleev O.V., 108
Malimon Y.I., 134
Markevich N.V., 98
Matlan V.L., 28, 93
Matsyk G.V., 235
Medinets Yu.R., 280
Miasoyedov D.V., 205
Mnishenko V.N., 32
Moshynska O.V., 32
N
Naleskina L.A., 187,
239
Nechai V.S., 131
Neiman A.M., 36
Nejko E.M., 51
Neprina G.S., 112
Nesina I.P., 14, 20
Nespriadko S.V., 190
Novak E.E., 14, 187
Novak O.Å., 251
Novak S.V., 28
Novak V.L., 93
O
Olijnichenko G.P., 36,
270
Orel V.E., 120
Osinsky D.S., 144, 305
Osinsky S.P., 292
Ð
Palivets A.Yu., 211, 280
Panasiuk A.A., 280
Paschenko S.N., 24
Pavlenko Yu.V., 137
Perepechkina V.T., 211
Petrukh A.V., 235, 258
Petrukhin V.I., 36
Philchenkov A.A., 170
Pivniuk V.M., 270
Polischuk E.V., 280
Polischuk L.Z., 14, 20,
187, 239
Polischuk R.S., 98, 235,
258
Protopopov A.O., 134
Protsenko V.V., 211, 280
Pryjmak V.V., 48, 129
Psaras G.G., 61, 122
Pushkar S.N., 237
õðîí³÷íà ë³ìôîöèòàðíà
ëåéêåì³ÿ, 89
Ö
öèñïëàòèí, 285
öèòîëîãè÷åñêàÿ
äèàãíîñòèêà, 225
öèòîìîðôîëîãèÿ, 252
×
÷àñòîòà, 206
Ý
ýêñïëàíòàòû îïóõîëè,
99, 263
ýêñïðåññ-îïðåäåëåíèå,
15
ýíäîëèìôàòè÷åñêàÿ
àíòèáèîòèêîòåðà-
ïèÿ, 121
ýíîêñàïàðèí íàòðèé
(ÊËÅÊÑÀÍ), 70,
130, 232
ýïèäåìèîëîãèÿ, 74
ýðèòðîöèòû, 29
ýòíè÷åñêèå ãðóïïû,
171
ýôôåêòèâíîñòü, 285
ýôôåêòèâíîñòü
ïðèìåíåíèÿ,
288
ß
ÿäåðöå, 18
Õ
õâîðîáà Ãîäæê³íà, 25
õèìèîòåðàïèÿ, 33, 62,
138, 145, 212, 263, 285
õèðóðãè÷åñêîå ëå÷åíèå,
42, 52, 59, 123, 228,
275, 277, 306
õîðèîíýïèòåëèîìà ó
ìàëü÷èêà, 225
õðîìîñîìíûå íàðóøå-
íèÿ, 9
AUTHOR INDEX
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002 319
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
A
ÀÂ0 and Rh systems, 235
acute intestinal obstruc-
tion, 55, 127
acute lymphoblastic leu-
kaemia in children,
214, 258
acute pancreatitis, 58
adjuvant therapy, 41
alkylating agents, 224
anemia, 298
angiogenesis, 251
anti-angiogenic treat-
ment, 251
anti-tumor chemothera-
py, 17
antitumor therapy, 292
apoptosis, 170
assessment of efficacy,
122
B
blast cells, 258
blood group antigens, 235
blood plasma, 28
brain tumors, 170
breast cancer, 24, 36, 39,
66, 84, 102, 106, 134,
150, 170, 203, 215,
233, 237, 267, 270, 274
C
cancer intoxication, 284
cancer of the larynx, 108
cancer of the pharynx,
108
cancer, 73, 193
carcinoma of uterine cer-
vix, 112
cardiañ tumors, 231, 310
CD95-receptor, 93
cell type, 262
ceramic material, 211
cerebral glioma, 196
cervical carcinoma, 190
chemotherapy, 36, 65,
144, 150, 214, 267,
287
children, 98
chorionepitelioma in
a boy, 227
chromosomal alterations,
14
chronic lymphocytic leu-
kaemia, 93
cisplatin, 287
clinical indicators, 262
clodronic acid, 270
CMF schedule, 150
colon cancer, 48, 55, 127,
129, 205, 276
colorectal cancer, 65, 131
combined methods, 48
combined treatment, 41,
129, 205
complications, 134, 211
computed tomography,
116
concurrent reactions, 214
corpus uteri cancer, 20
culturing, 102, 267
cytological diagnostics,
227
cytomorphology, 255
D
depression, 106
diagnosis, 231, 310
diagnostic efficiency, 116
diagnostics, 158
differential hystologic
diagnosis, 183
differentiated thyroid
cancer, 199
diffuse cameras, 102, 267
diffuse mastopathy, 193
discriminant analysis, 55,
127, 262
dislipoproteinemia, 237
DNA topoisomerase II
inhibitors, 224
Å
efficacy of application, 292
efficacy, 41, 48, 134, 270
efficiency, 287
endocrinotherapy, 102
endolymphatic antibiotic
treatment, 122
enoxaparin natricum
(CLEXANE), 73
enterosorbents, 51
epidemiology, 77
erythrocytes, 32
estrogen and progeste-
rone receptors, 36,
102, 267
ethnic groups, 173
exposure of blood to ul-
traviolet, 284
F
fibroadenoma, 193
G
gastric cancer, 84, 120,
158
gastrointestinal malignan-
cies, 170
genetic mutations, 235
genito-urinary carcino-
mas, 170
R
Rachynska N.O., 235
Rogova N.M., 112
Romanenko A.M., 187
Romaniuk A.N., 231
Rozenfield L.G., 108
Rudaya O.I., 227
Rudenko E.V., 231, 310
S
Schepotin I.B., 158
Senishin N.I., 235
Senko L.N., 144
Senyutovich R.V., 79
Shabeliansky V.B., 134
Shalimov S.O., 205
Shparyk Yà.V., 150
Shudrak A.A., 131
Simonova L.I., 237
Siniavina L.V., 193
Sirotkina N.P., 112
Sivkovich S.A., 137
Skoropad L.L., 98
Slinko Å.I., 45
Smakova M.S., 227
Smolanka I.I., 227
Solovyov I.E., 55, 127
Sorkin V.M., 274
Sorokin B.V., 48, 129
Sorokina K.E., 137
Sozoniuk L.I., 203
Spivak S.I., 102
Starikov V.I., 116
Stepaniuk O.I., 98
Sukhoversha A.A., 233
Suprunets V.L., 134
Susak Ya.M., 58
T
Tarasova T.A., 280
Tashcuk I.V., 39
Tkachenko N.I., 20
Todor I.M., 8
Tofan A.V., 55, 127
Tolstopyatov B.O., 211,
280
Tomilina N.A., 137
Tretiak N.N., 32
Troyanovska O.O., 98,
235
Trukhin D.V., 122
Tryndiak V.P., 8
Tsiapka O.M., 93
Tsip N.P., 77
Tsymbaliuk I.P., 98
Tuganova T.N., 227, 255
U
Usatov S.A., 196
V
Vakulchuk A.M., 32
Valetsky V.L., 120
Varon R., 98
Vasilyuk O.M., 211
Vasyliev S.D., 61
Vatin O.E., 112
Velichko L.N., 262
Vilchevskaya E.V., 214
Vinnychouk Yu.D., 102
Vinnytska A.B., 41, 190
Vit V.V., 262
Vitovsky R.M., 231, 310
Vivcharenko Yu.K., 51
Volkov I.B., 211
Voloshyn N.A., 24
Vorobieva L.I., 73
Vorontsova A.L., 203
Vovk G.P., 235
Vygovska Ya.I., 28, 93, 258
Y
Yagovdick M.V., 32
Yakymchook P.M., 203
Yaremchouk A.Ya., 102
Yaroshenko M.V., 61
Yemets I.N., 231
Yevtushenko O.I., 205
Yugrinov O.G., 129, 305
Yusupov B.Y., 173
Z
Zabarko L.B., 187
Zagurska N.O., 284
Zakharova V.P., 310
Zakhartseva L.M., 36,
187, 102, 267
Zavizion V.F., 233
Zhylchook V.Y., 203,
Zolotukhin S.E., 61, 122
KEY WORD INDEX
ÓÊÀÇÀÒÅËÈ 4 ÒÎÌÀ (2002)
ÎÍÊÎËÎÃÈß � Ò. 4 � ¹ 4 � 2002320
giant-cell proliferative
bone affections, 183
gynecological malignan-
cies, 170
Í
hematooncologic disea-
ses, 98
hemorheology, 298
HER-2/neu, 36, 267
Hodgkin’s disease, 28
hormonotherapy, 274
hydatidiform mole, 77
hydroxylapatite, 211
hyperthermia (local, to-
tal), 292
hysterocarcinoma, 112
hystopathology, 183
I
immune cytopenia, 93
immunocorrection, 112
immunoenzymic
method, 190
immunogram, 120
immunohystochemistry,
183
immunophenotype, 258
immunological indica-
tors, 262
in vitro assay, 17
indirect electrochemical
oxidation of blood, 284
individual susceptibility, 17
inflammatory complica-
tions, 122
inoperable tumor, 144
interferon inductors, 196
interferon, 203
interferongenesis, 196
interleukin-2, 28
intestinal obstruction, 127
intraarterial polychemo-
therapy, 129, 280
intraoperative cryode-
struction and sponta-
neous thawing, 205
ionizing radiation, 224
irinotecan (CAMPTO),
65, 84, 287
L
lectins, 24
leukemia, 235
leukopenia, 137
limphokine-activated cy-
totoxicity, 28
lipid peroxidation, 32
lipoproteins, 193
liver, 65
local hyperthermia (mag-
netothermia), 280
loss of heterozygosity, 14
low abdominal-anal re-
section, 61
low-energy laser therapy,
284
lung cancer, 233
lymphocytes, 20, 28
lymphogranulomatosis,
137
lymphoid cells, 255
lymphoid thymoma, 255
M
magnetic resonance to-
mography, 116
malignant limphomas, 28
malignant neoplasm of
bones, 211
malignant tumors, 58,
251, 298
mammary gland, 193
mastectomy, 106
MEBIPHON, 270
mechanisms of action, 292
mediastinum tumors, 116
melatonin, 39
membrane of erythro-
cytes, 298
mesothelioma, 170
metaphylaxis, 108
metastases, 65, 270
metastasizing, 24, 298
methotrexate, 214
morbidity rate, 173
morphological indicators,
262
morphology, 14, 310
morphometry, 255
multiple myeloma, 32
N
neoadjuvant polychemo-
therapy, 39
neoadjuvant therapy, 41
neoplasms of soft tissues,
170
Nijmegen Breakage Syn-
drome, 98
normal and tumor cells, 8
nucleolus, 20
O
oncogenes, 14
one-year survival, 120
organ-conserving treat-
ment, 203
organ-preserving treat-
ment, 134
osteo-plastics operations,
211
ovarian cancer, 14, 84
ovarian carcinoma, 112
P
pancreatic cancer, 144,
305
papillary fibroelastoma,
310
peroxide oxidation of li-
pids, 298
plasma, 32
plasmatic membrane, 8
polychemotherapy, 112,
137
POLYDAN, 112, 137
post-surgery immuno-
therapy, 120
prevention, 131, 158, 233
primary multiple tumors,
274
prognosis, 14, 32, 208
prognostic factors, 276
proliferating cell nuclear
antigen (PCNA), 187
proliferation, 170
proliferative activity of
tumor cells, 187
prophylaxis, 73
prostatic cancer, 270
pshychorehabilitation,
106
psychosomatics, 106
R
radiation therapy, 137,
280
radical treatment, 48
radioiodine therapy, 199
radiomodificators, 51
radiotherapy, 51, 108, 211
rate, 208
receptors, 24
rectal cancer, 51, 61, 122,
208
regional chemotherapy,
305
relapse, 208, 211
residual thyroid tissue, 199
results of therapy, 305
results of treatment, 144
rhabdomyoma, 231
risk factors, 77
roentgenologic examina-
tion, 116
S
secondary leukemia, 224
serous ovarian neoplasms,
187
signal transduction sys-
tem, 8
singlet oxygen therapy,
51
small-call lung cancer,
287
snap analysis, 17
sodium enoxaparine
(CLEXAN), 131, 233
soft part sarcoma, 280
splenectomy, 93
surgery, 127, 280
surgical treatment, 45,
55, 61, 231, 276, 310
survival, 170
T
therapy-induced leuke-
mia, 224
thermography, 108
thromboembolic compli-
cations, 131, 233
thymus, 255
thyreoidectomy, 199
thyroid gland cancer, 173
topotecan, 287
total cholesterol, 193
transitive and malignant
spinal vascular tu-
mors, 45
treatment of cancer pa-
tients, 8
treatment, 158
triglycerides, 193
tumor explants, 102, 267
tumor suppressor genes, 14
tumors and tumor-like
bone affections, 183
tumors of respiratory or-
gans, 170
U
uterine carcinoma, 190
uterine neck cancer, 41
uveal melanoma, 262
Uzbekistan, 173
V
vascular endothelial
growth factor
(VEGF), 190, 251
venous thromboembo-
lism, 73
vincristine, 93
|
| id | nasplib_isofts_kiev_ua-123456789-24717 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1562-1774,0204-3564 |
| language | Russian |
| last_indexed | 2025-12-07T19:06:03Z |
| publishDate | 2002 |
| publisher | Iнститут експериментальної патології, онкології і радіобіології ім. Р. Є. Кавецького |
| record_format | dspace |
| spelling | 2011-07-21T11:05:08Z 2011-07-21T11:05:08Z 2002 Указатели 4 тома (2002) / // Онкологія. — 2002. — Т. 4, № 4. — С. 315-320. — Бібліогр.: 0 назв. — рос. 1562-1774,0204-3564 https://nasplib.isofts.kiev.ua/handle/123456789/24717 ru Iнститут експериментальної патології, онкології і радіобіології ім. Р. Є. Кавецького Онкологія Информация Указатели 4 тома (2002) Article published earlier |
| spellingShingle | Указатели 4 тома (2002) Информация |
| title | Указатели 4 тома (2002) |
| title_full | Указатели 4 тома (2002) |
| title_fullStr | Указатели 4 тома (2002) |
| title_full_unstemmed | Указатели 4 тома (2002) |
| title_short | Указатели 4 тома (2002) |
| title_sort | указатели 4 тома (2002) |
| topic | Информация |
| topic_facet | Информация |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/24717 |